-
1
-
-
84908689124
-
-
Accessed July 1, 2013
-
American Cancer Society. Leading New Cancer Cases and Deaths-2013 Estimates. Available at: http://www.cancer.org/research/cancerfactsstatistics/cancerfactsfgures2013/index. Accessed July 1, 2013.
-
Leading New Cancer Cases and Deaths-2013 Estimates
-
-
-
3
-
-
80054690379
-
Characterising the castration-resistant prostate cancer population: A systematic review
-
Kirby M, Hirst C, Crawford ED. Characterising the castration-resistant prostate cancer population: a systematic review. Int J Clin Pract 2011;65:1180-1192.
-
(2011)
Int J Clin Pract
, vol.65
, pp. 1180-1192
-
-
Kirby, M.1
Hirst, C.2
Crawford, E.D.3
-
4
-
-
84872078210
-
Abiraterone in metastatic prostate cancer without previous chemotherapy
-
Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013;368:138-148.
-
(2013)
N Engl J Med
, vol.368
, pp. 138-148
-
-
Ryan, C.J.1
Smith, M.R.2
De Bono, J.S.3
-
5
-
-
77955066199
-
Sipuleucel-T immunotherapy for castration-resistant prostate cancer
-
Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010;363:411-422.
-
(2010)
N Engl J Med
, vol.363
, pp. 411-422
-
-
Kantoff, P.W.1
Higano, C.S.2
Shore, N.D.3
-
7
-
-
84863323889
-
-
Horsham PA: Centocor Ortho Biotech
-
Zytiga [package insert]. Horsham, PA: Centocor Ortho Biotech; 2011.
-
(2011)
Zytiga [Package Insert]
-
-
-
8
-
-
79959282824
-
Translating scientifc advancement into clinical beneft for castration-resistant prostate cancer patients
-
Attard G, de Bono JS. Translating scientifc advancement into clinical beneft for castration-resistant prostate cancer patients. Clin Cancer Res 2011;17:3867-3875.
-
(2011)
Clin Cancer Res
, vol.17
, pp. 3867-3875
-
-
Attard, G.1
De Bono, J.S.2
-
9
-
-
79957443342
-
Abiraterone and increased survival in metastatic prostate cancer
-
de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011;364:1995-2005.
-
(2011)
N Engl J Med
, vol.364
, pp. 1995-2005
-
-
De Bono, J.S.1
Logothetis, C.J.2
Molina, A.3
-
10
-
-
84908673797
-
-
Seattle WA : Dendreon Corporation; June
-
Provenge [package insert]. Seattle, WA : Dendreon Corporation; June 2011.
-
(2011)
Provenge [Package Insert]
-
-
-
11
-
-
84878089792
-
Therapeutic options in docetaxel-refractory metastatic castration-resistant prostate cancer: A cost-effectiveness analysis
-
Zhong L, Pon V, Srinivas S, et al. Therapeutic options in docetaxel-refractory metastatic castration-resistant prostate cancer: a cost-effectiveness analysis. PLoS One 2013;8:e64275.
-
(2013)
PLoS One
, vol.8
, pp. e64275
-
-
Zhong, L.1
Pon, V.2
Srinivas, S.3
-
12
-
-
84893650152
-
Abiraterone for Castration-Resistant Metastatic Prostate Cancer Previously Treated with a Docetaxel-Containing Regimen
-
Accessed July 1, 2013
-
National Institute for Health and Clinical Excellence. Abiraterone for Castration-Resistant Metastatic Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen. NICE Technology Appraisal Guidance, 2012. Available at: guidance.nice.org.uk/ta259. Accessed July 1, 2013.
-
(2012)
NICE Technology Appraisal Guidance
-
-
-
13
-
-
84908681576
-
Prostate Cancer (Metastatic, Hormone Relapsed)-Sipuleucel-T (1st Line) [ID573]
-
Accessed August 1, 2013
-
National Institute for Health and Care Excellence. Prostate Cancer (Metastatic, Hormone Relapsed)-Sipuleucel-T (1st Line) [ID573]. NICE Technology Appraisal Guidance. Available at: http://guidance.nice.org.uk/TA/WaveR/156#keydocs. Accessed August 1, 2013.
-
NICE Technology Appraisal Guidance
-
-
-
14
-
-
84857397717
-
Interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer
-
Huber ML, Haynes L, Parker C, Iversen P. Interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer. J Natl Cancer Inst 2012;104:273-279.
-
(2012)
J Natl Cancer Inst
, vol.104
, pp. 273-279
-
-
Huber, M.L.1
Haynes, L.2
Parker, C.3
Iversen, P.4
-
15
-
-
78650809219
-
-
Accessed July 1, 2013
-
Cleeland CS. Brief Pain Inventory User Guide. Available at: http://www.mdanderson.org/education-and-research/departments-programs-and-labs/departments-and-divisions/symptom-research/symptom-assessment-tools/BPI-UserGuide.pdf. Accessed July 1, 2013.
-
Brief Pain Inventory User Guide
-
-
Cleeland, C.S.1
-
16
-
-
0020396015
-
Toxicity and response criteria of the Eastern Cooperative Oncology Group
-
Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-655.
-
(1982)
Am J Clin Oncol
, vol.5
, pp. 649-655
-
-
Oken, M.M.1
Creech, R.H.2
Tormey, D.C.3
-
17
-
-
0020357091
-
A convenient approximation of life expectancy (the "dEALE"). I. Validation of the method
-
Beck JR, Kassirer J P, Pauker SG. A convenient approximation of life expectancy (the "DEALE"). I. Validation of the method. Am J Med 1982;73:889-897.
-
(1982)
Am J Med
, vol.73
, pp. 889-897
-
-
Beck, J.R.1
Kassirer, J.P.2
Pauker, S.G.3
-
18
-
-
67651123901
-
-
Accessed August 1, 2013
-
Social Security Administration. Period Life Table, 2010. Available at: http://www.ssa.gov/OACT/STATS/table4c6.html#ss. Accessed August 1, 2013.
-
(2010)
Period Life Table
-
-
-
19
-
-
84908681575
-
-
Accessed September 13, 2014
-
US Department of Veterans Affairs. Veterans Affairs Federal Supply Schedule. Contract Catalog. Available at: http://www.va.gov/nac/index.cf m?action=search&template=Search-Pharmaceutical-Catalog. Accessed September 13, 2014.
-
Veterans Affairs Federal Supply Schedule. Contract Catalog
-
-
-
20
-
-
84871332039
-
-
Fourth Edition. Available at Accessed June 1, 2013
-
Centers for Medicare and Medicaid Services (CMS). Current Procedural Terminology, Fourth Edition. Available at: http://www.cms.gov/apps/physician-fee-schedule/. Accessed June 1, 2013.
-
Current Procedural Terminology
-
-
-
21
-
-
0035397976
-
Estimating the cost of informal caregiving for elderly patients with cancer
-
Hayman JA, Langa KM, Kabeto MU, et al. Estimating the cost of informal caregiving for elderly patients with cancer. J Clin Oncol 2001;19:3219-3225.
-
(2001)
J Clin Oncol
, vol.19
, pp. 3219-3225
-
-
Hayman, J.A.1
Langa, K.M.2
Kabeto, M.U.3
-
22
-
-
44049089885
-
-
Bureau of Labor Statistics Web site Accessed June 1, 2013
-
United States Department of Labor. National Compensation Survey: Employer Cost for Employee Compensation. Bureau of Labor Statistics Web site. Available at: http://www.bls.gov/ncs/data.htm. Accessed June 1, 2013.
-
National Compensation Survey: Employer Cost for Employee Compensation
-
-
-
23
-
-
84908674328
-
-
Accessed July 1, 2013
-
Centers for Medicare and Medicaid Services (CMS). Medicare Fee For Service Payment-Acute Inpatient PPS. Available at: http://www.cms. gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/Acute-Inpatient-Files-for-Download-Items/FY2013-FinalRule-CorrectionNotice-Files.html?DLPage=1&DLSort=1&DLSortDir=descen ding. Accessed July 1, 2013.
-
Medicare Fee for Service Payment-Acute Inpatient PPS
-
-
-
24
-
-
84874903258
-
Long-term costs of ischemic stroke and major bleeding events among Medicare patients with nonvalvular atrial fbrillation
-
Mercaldi CJ, Siu K, Sander SD, et al. Long-term costs of ischemic stroke and major bleeding events among Medicare patients with nonvalvular atrial fbrillation. Cardiol Res Pract 2012;2012:645469.
-
(2012)
Cardiol Res Pract
, vol.2012
, pp. 645469
-
-
Mercaldi, C.J.1
Siu, K.2
Sander, S.D.3
-
25
-
-
33846954758
-
Aspirin for the primary prevention of cardiovascular disease in women: A cost-utility analysis
-
Pignone M, Earnshaw S, Pletcher MJ, et al. Aspirin for the primary prevention of cardiovascular disease in women: a cost-utility analysis. Arch Intern Med 2007;167:290-295.
-
(2007)
Arch Intern Med
, vol.167
, pp. 290-295
-
-
Pignone, M.1
Earnshaw, S.2
Pletcher, M.J.3
-
26
-
-
33846251498
-
Long-term costs and resource use in elderly participants with congestive heart failure in the Cardiovascular Health Study
-
Liao L, Anstrom KJ, Gottdiener JS, et al. Long-term costs and resource use in elderly participants with congestive heart failure in the Cardiovascular Health Study. Am Heart J 2007;153:245-252.
-
(2007)
Am Heart J
, vol.153
, pp. 245-252
-
-
Liao, L.1
Anstrom, K.J.2
Gottdiener, J.S.3
-
27
-
-
84869781090
-
One-year follow-up healthcare costs of patients hospitalized for transient ischemic attack or ischemic stroke and discharged with aspirin plus extended-release dipyridamole or clopidogrel
-
Burton TM, Lacey M, Liu F, et al. One-year follow-up healthcare costs of patients hospitalized for transient ischemic attack or ischemic stroke and discharged with aspirin plus extended-release dipyridamole or clopidogrel. J Med Econ 2012;15:1217-1225.
-
(2012)
J Med Econ
, vol.15
, pp. 1217-1225
-
-
Burton, T.M.1
Lacey, M.2
Liu, F.3
-
28
-
-
84865249876
-
Healthcare resource use in advanced prostate cancer patients treated with docetaxel
-
Mehra M, Wu Y, Dhawan R. Healthcare resource use in advanced prostate cancer patients treated with docetaxel. J Med Econ 2012;15:836-843.
-
(2012)
J Med Econ
, vol.15
, pp. 836-843
-
-
Mehra, M.1
Wu, Y.2
Dhawan, R.3
-
31
-
-
34249034665
-
A review and meta-analysis of prostate cancer utilities
-
Bremner KE, Chong CA, Tomlinson G, et al. A review and meta-analysis of prostate cancer utilities. Med Decis Making 2007;27:288-298.
-
(2007)
Med Decis Making
, vol.27
, pp. 288-298
-
-
Bremner, K.E.1
Chong, C.A.2
Tomlinson, G.3
-
32
-
-
1942467444
-
Preferences of husbands and wives for outcomes of prostate cancer screening and treatment
-
Volk RJ, Cantor SB, Cass AR, et al. Preferences of husbands and wives for outcomes of prostate cancer screening and treatment. J Gen Intern Med 2004;19:339-348.
-
(2004)
J Gen Intern Med
, vol.19
, pp. 339-348
-
-
Volk, R.J.1
Cantor, S.B.2
Cass, A.R.3
-
33
-
-
0030841253
-
A comparison of perspectives on prostate cancer: Analysis of utility assessments of patients and physicians
-
Bennett CL, Chapman G, Elstein AS, et al. A comparison of perspectives on prostate cancer: analysis of utility assessments of patients and physicians. Eur Urol 1997;32(Suppl 3):86-88.
-
(1997)
Eur Urol
, vol.32
, pp. 86-88
-
-
Bennett, C.L.1
Chapman, G.2
Elstein, A.S.3
-
34
-
-
84908681574
-
Cost-utility analysis of enzalutamide versus abiraterone for the treatment of docetaxel refractory metastatic castrate resistant prostate cancer
-
Presented at the May 18-22 New Orleans, Louisiana. Poster PCN86
-
Yeung K, Gong CL. Cost-utility analysis of enzalutamide versus abiraterone for the treatment of docetaxel refractory metastatic castrate resistant prostate cancer. Presented at the 18th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research; May 18-22, 2013; New Orleans, Louisiana. Poster PCN86.
-
(2013)
18th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research
-
-
Yeung, K.1
Gong, C.L.2
-
35
-
-
84908681573
-
Cost-Effectiveness Thresholds
-
Accessed August 1, 2013
-
World Health Organization. Cost-Effectiveness Thresholds. CHOosing Interventions that are Cost-Effective (WHO-CHOICE). Available at: http://www.who.int/choice/costs/CER-thresholds/en/. Accessed August 1, 2013.
-
CHOosing Interventions That Are Cost-Effective (WHO-CHOICE)
-
-
-
36
-
-
0031900689
-
Net health benefts: A new framework for the analysis of uncertainty in cost-effectiveness analyses
-
Stinnett AA, Mullahy J. Net health benefts: a new framework for the analysis of uncertainty in cost-effectiveness analyses. Med Decis Making 1998;18:S68-80.
-
(1998)
Med Decis Making
, vol.18
, pp. S68-80
-
-
Stinnett, A.A.1
Mullahy, J.2
-
37
-
-
85038645694
-
Using net benefts to report cost-effectiveness results
-
Presented at the Accessed August 1, 2013
-
O'Day K, Globe D. Using net benefts to report cost-effectiveness results. Presented at the ISPOR Annual European Congress; November 5-8, 2011. Available at: http://www.ispor.org/congresses/Spain1111/presentations/W30-Globe-Oday.pdf. Accessed August 1, 2013.
-
(2011)
ISPOR Annual European Congress; November 5-8
-
-
O'Day, K.1
Globe, D.2
-
38
-
-
10844271622
-
Study of hormone refractory prostate cancer: Hospital care and palliative care resource use at a VA medical center
-
Hwang SS, Chang VT, Alejandro Y, Mulaparthi S, et al. Study of hormone refractory prostate cancer: hospital care and palliative care resource use at a VA medical center. Cancer Invest 2004;22:849-857.
-
(2004)
Cancer Invest
, vol.22
, pp. 849-857
-
-
Hwang, S.S.1
Chang, V.T.2
Alejandro, Y.3
Mulaparthi, S.4
-
39
-
-
84878601468
-
Lower baseline prostate-specifc antigen is associated with a greater overall survival beneft from sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) trial
-
Schellhammer P F, Chodak G, Whitmore JB, et al. Lower baseline prostate-specifc antigen is associated with a greater overall survival beneft from sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) trial. Urology 2013;81:1297-1302.
-
(2013)
Urology
, vol.81
, pp. 1297-1302
-
-
Schellhammer, P.F.1
Chodak, G.2
Whitmore, J.B.3
-
41
-
-
32944472716
-
Do oncologists believe new cancer drugs offer good value?
-
Nadler E, Eckert B, Neumann PJ. Do oncologists believe new cancer drugs offer good value? Oncologist 2006;11:90-95.
-
(2006)
Oncologist
, vol.11
, pp. 90-95
-
-
Nadler, E.1
Eckert, B.2
Neumann, P.J.3
|